ClinicalTrials.gg

Program

polfurmetinib

Also written as “Oral [14C] PF-07799544”, “Oral Unlabeled PF-07799544” and “IV [14C] PF-07799544”.

In Pfizer's pipeline, MEK brain penetrant inhibitor. Its studies are mostly in Melanoma, led by Pfizer.

Furthest: phase 1, since Sep 9, 20223 company-led studies, 1 open or runningNext primary completion: Aug 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer31 open or runningphase 1since Sep 9, 2022Sep 9, 2022Aug 31, 2027phase 1 · NCT05538130
  • Named in Pfizer’s own pipeline as polfurmetinib PF-07799544, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2022First study: phase 1 study in MelanomaFirst studyNCT05538130 · 148 enrolled · United States, Australia, Brazil and more
  2. Apr 6, 2026Phase 1 study in HealthyNCT07563894 · 16 enrolled · United States
  3. May 5, 2026Phase 1 study in Healthy Male VolunteersNCT07578636 · 9 enrolled · United States

Ahead

  1. Aug 31, 2027Primary completion: phase 1 study in MelanomaNCT05538130

TargetBeta

“MEK brain penetrant inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable, brain penetrating inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPKK; MEK), with potential antineoplastic activity. Upon oral administration, polfurmetinib specifically targets, binds to and inhibits the catalytic activity of MEK, thereby inhibiting the act…”NCIt, read by Claude

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
cobimetinibruleHoffmann-La Rochephase 338
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07578636Healthy Male Volunteers · United States1CompletedJul 2, 20269
NCT07563894Healthy · United States1CompletedJun 24, 202616
NCT05538130Melanoma · United States, Australia, Brazil and more1Active, not recruitingAug 31, 2027148

How it is read

Names in the registry

  • “Oral [14C] PF-07799544”, 1 entry
  • “Oral Unlabeled PF-07799544”, 1 entry
  • “IV [14C] PF-07799544”, 1 entry
  • “PF-07799544”, 1 entry
  • “PF-07799933 tablets with PF-07799544 fasted”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.